MX2023012703A - Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave. - Google Patents
Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave.Info
- Publication number
- MX2023012703A MX2023012703A MX2023012703A MX2023012703A MX2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- myasthenia gravis
- treat
- treat myasthenia
- inebilizumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185613P | 2021-05-07 | 2021-05-07 | |
| US202263303655P | 2022-01-27 | 2022-01-27 | |
| PCT/US2022/028063 WO2022236047A1 (en) | 2021-05-07 | 2022-05-06 | Use of an anti-cd19 antibody to treat myasthenia gravis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012703A true MX2023012703A (es) | 2023-11-21 |
Family
ID=81846343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012703A MX2023012703A (es) | 2021-05-07 | 2022-05-06 | Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240270842A1 (enExample) |
| EP (1) | EP4333987A1 (enExample) |
| JP (1) | JP2024518410A (enExample) |
| KR (1) | KR20240004367A (enExample) |
| AU (1) | AU2022270697A1 (enExample) |
| BR (1) | BR112023022133A2 (enExample) |
| CA (1) | CA3217586A1 (enExample) |
| IL (1) | IL308296A (enExample) |
| MX (1) | MX2023012703A (enExample) |
| WO (1) | WO2022236047A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024155810A1 (en) * | 2023-01-20 | 2024-07-25 | Viela Bio, Inc. | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| EA010594B1 (ru) | 2001-05-24 | 2008-10-30 | Займодженетикс, Инк. | Слитые белки taci-иммуноглобулина |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| PT2272868E (pt) | 2003-06-05 | 2015-07-07 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| JP5401314B2 (ja) | 2006-09-08 | 2014-01-29 | メディミューン,エルエルシー | ヒト化抗cd19抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| WO2009052431A2 (en) * | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| JP2012518404A (ja) * | 2009-02-23 | 2012-08-16 | グレンマーク・ファーマシューティカルズ・エスエー | Cd19に結合するヒト化抗体及びその使用 |
| EP3157553A4 (en) | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| JP2019515874A (ja) | 2016-03-01 | 2019-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 改変された細胞死誘導を有するオビヌツズマブ変異体 |
| CN113939532A (zh) * | 2019-04-24 | 2022-01-14 | 维埃拉生物股份有限公司 | 使用抗cd19抗体治疗自身免疫性疾病 |
-
2022
- 2022-05-06 CA CA3217586A patent/CA3217586A1/en active Pending
- 2022-05-06 EP EP22725660.9A patent/EP4333987A1/en active Pending
- 2022-05-06 MX MX2023012703A patent/MX2023012703A/es unknown
- 2022-05-06 IL IL308296A patent/IL308296A/en unknown
- 2022-05-06 KR KR1020237036834A patent/KR20240004367A/ko active Pending
- 2022-05-06 US US18/559,195 patent/US20240270842A1/en active Pending
- 2022-05-06 JP JP2023568333A patent/JP2024518410A/ja active Pending
- 2022-05-06 WO PCT/US2022/028063 patent/WO2022236047A1/en not_active Ceased
- 2022-05-06 AU AU2022270697A patent/AU2022270697A1/en active Pending
- 2022-05-06 BR BR112023022133A patent/BR112023022133A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024518410A (ja) | 2024-05-01 |
| EP4333987A1 (en) | 2024-03-13 |
| IL308296A (en) | 2024-01-01 |
| US20240270842A1 (en) | 2024-08-15 |
| WO2022236047A9 (en) | 2023-09-21 |
| BR112023022133A2 (pt) | 2023-12-26 |
| KR20240004367A (ko) | 2024-01-11 |
| AU2022270697A1 (en) | 2023-10-19 |
| WO2022236047A1 (en) | 2022-11-10 |
| CA3217586A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020219743A3 (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| ZA202400108B (en) | A group of b7h3 monoclonal antibodies and medical use thereof | |
| ZA202106131B (en) | Bcma monoclonal antibody-drug conjugate | |
| MX2025000067A (es) | Anticuerpo anti glicoproteina de transmembrana mucina-1 (muc1) | |
| WO2020016662A3 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| WO2012048332A3 (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| UA97946C2 (ru) | Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека | |
| IL187594A0 (en) | Humanized anti-cd40 antibodies and their methods of use | |
| MA39821A (fr) | Molécules de liaison spécifiques de l'il-21 et leurs utilisations | |
| PH12020550933A1 (en) | Antibodies binding ctla-4 and uses thereof | |
| SA521430654B1 (ar) | مستقبلات مولِّدات ضد خيميرية مقاومة للريتوكسيماب واستخداماتها | |
| IL315353A (en) | HU14.18K322A monoclonal antibody production process | |
| JOP20190002A1 (ar) | أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم | |
| MX2012002427A (es) | Anticuerpos anticina que se unen a quimiocinas cc multiples. | |
| NZ595863A (en) | Antibodies to egfl7 and methods for their use | |
| WO2016205551A3 (en) | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function | |
| NZ770219A (en) | Monoclonal antibodies against human tim-3 | |
| HK1253693A1 (zh) | 产生抗t细胞受体的抗体的方法 | |
| DK1641828T3 (da) | Anti-HGF-R-antistoffer og deres anvendelse | |
| SG11201908659RA (en) | Chimeric antigen receptor | |
| EP1357132A3 (en) | Detection of the her2 receptor by means of biotinylated humanized antibody | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| PH12022552725A1 (en) | Anti-ox40 antibody and uses thereof | |
| MX2022014525A (es) | Inmunoglobulina hipersialilada. |